IMMvention Therapeutix, Inc. is an early-stage biotechnology company based in Durham, North Carolina, focused on discovering and developing novel oral small-molecule therapeutics for diseases with high unmet medical need, including sickle cell disease and other chronic conditions. The company’s pipeline centers on first-in-class BACH1 inhibitors designed to modulate key cellular pathways, with the potential to increase fetal hemoglobin and address inflammation and oxidative stress. IMMvention has established a strategic collaboration with Novo Nordisk to co-develop orally dosed BACH1 programs for sickle cell disease and beyond, advancing its mission to create globally accessible medicines.

 

VISIT WEBSITE